UCB's Global Corporate Website
Welcome to UCB in the United States

Jul

21

UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

Jun

27

Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis

Jun

27

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

Jun

14

How UCB Is Supporting the Mental Health of Patients and Caregivers

Jun

14

Recognizing Ethical Leadership at UCB

Jun

08

Employee Spotlight: Natasha Trujillo’s Passion for Advocacy

Jun

02

Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

Jun

01

Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community

May

08

Celebrating Asian American and Pacific Islander Heritage Month with our ACES Employee Resource Group

Apr

27

Voices on Value: Breaking Down the Value Chain: The Policies Impacting Patients